Study On The Relationships Of Acute Phase Serum Amyloid Protein A, Obesity And Its Metabolic Complications

Background and Objective:To investigate the effects of acute phase serum amyloid protein A (A-SAA) and rosiglitazone on the gene expression of pro-infammatory cytokines in endothelial cells, and to explore the effects of rosiglitazone on A-SAA, high sensitivity C-reactive protein (hsC-RP), the other adipokines, lipids and glucose metabolism, insulin resistance (IR) in impaired glucose regulation (IGR) and new-onset type 2 diabetes mellitus (T2DM) subjects. As an acute phase reactant, the liver is thought to be the primary source of circulating A-SAA. In several observational and prospective studies, A-SAA levels are elevated in conditions associated with increased cardiovascular risk, including obesity, IR, the metabolic syndrome (MS) and T2DM. A-SAA levels decreased significantly after weight loss in obese subjects, as well as in subjects treated with rosiglitazone. A-SAA has also been shown to be an independent predictor of cardiovascular diseases (CVD). Recent study indicates that the A-SAA is selectively expressed in human adipose cells and that its serum levels are positively correlated with body mass index (BMI). These data demonstrate that A-SAA is an adipokine in humans and a direct link between obesity and its comorbidities such as IR, T2DM and atherosclerosis. However, it is not well know the role of A-SAA in obesity and its comorbidities such as IR, T2DM and atherosclerosis.Methods:1. Total RNA of ECV304 endothelial cells incubated with 0.5μg/ml, 5μg/ml A-SAA and rosiglitazone (10μM) for 8 hours or 24 hours was...